Dr. Clay Siegall Talks about the Seattle Genetics’ Latest Drug Regimen

Seattle Genetics is involved in conducting intensive scientific research. This company is famous for manipulating human antibodies to create different drugs. Seattle Genetics boasts of a net worth of more than $10 billion and works with a pool of more than 100 employees. Seattle has been ranked as the best performing pharmaceutical business in Washington, D.C.

Types of drugs manufactured by Seattle Genetics

One of its drugs that have made the headlines is Adcetris, a drug that treats Hodgkin lymphoma, a medical condition that affects the lymphatic system. Seattle Genetics anticipates starting marketing this drug in the coming weeks. Dr. Siegall desires to sell Seattle Genetics’ drugs on an international platform. Seattle Genetics has worked closely with Takeda Oncology in raising capital to fund the manufacturing of Adcetris. This company also plans to combine Adcetris with other immunotherapies, such as Opdivo, to make it have multiple uses. According to Adam Feuerstein, this approach will enable Seattle Genetics to build additional markets.

The Association of Health Insurance Plans anticipates that the cost of treatment for Hodgkin Lymphoma using Adcetris will range from $230,000 to $330,000. The funds raised will be used to fund more research activities. Another drug that has become popular is the 33A that is used to treat myeloid leukemia, a form of cancer that affects the myeloid cells. Seattle Genetics is also the manufacturer of 22ME used to treat urothelial and bladder cancers. Additionally, it has also launched an extensive regimen to treat breast cancer. In the next couple of years, Seattle Genetics will become the sole manufacturer of cancer therapies.

About Clay Siegall

Clay Siegall is a biotech guru and the founder of Seattle Genetics. Dr. Clay Siegall has worked with numerous pharmaceutical companies to develop various drugs. He has pioneered in the development of targeted cancer therapies that have found their way to the global market. Dr. Siegall is a graduate of the University of Maryland where he studied zoology and the George Washington University where he acquired his doctorate.

Under his leadership, Seattle Genetics has manufactured more than 20 drugs that are in various stages of development. Dr. Clay Siegall works in partnership with other esteemed pharmaceutical companies, such as Pfizer, Bayer, and Genentech. The FDA has already approved several drugs used to treat different conditions. Dr. Siegall is famous for developing the first antibody-drug conjugates. Most the drugs this company makes are composed of this key ingredient. This entrepreneur plans to expand the company’s portfolio by a huge margin in the coming years.